Table 1

Patient characteristics (n = 30)
  Characteristic No. of patients % patients
Age (years)
  Median (range) 65 (42–81)
Gender
  Male 16 53
  Female 14 47
Karnofsky performance status
  90-100 22 73
  70-80 8 27
  0-60 0 0
Tumor location
  Head 15 50
  Body and Tail 15 50
Nodal status
  Negative 18 60
  Positive 12 40
Baseline tumor diameter (cm)
  Median (range) 4.5 (2.1-7.8)
Baseline serum CA19-9 level (U/ml)
  Median (range) 872 (0–35490)
  ≥ 1,000 14 47
  100-1,000 11 37
  < 100 5 17
Pre-CRT tumor diameter (cm)
  Median (Range) 4.1 (1.9-8.4)
Pre-CRT serum CA19-9 Level (U/ml)
  Median 631 (0–50440)
  ≥ 1,000 11 37
  100-1,000 12 40
  < 100 7 23
Regimens of primary chemotherapy
  Gemcitabine alone 24 80
  Gemcitabine + α 6 20

CRT chemoradiotherapy.

Mayahara et al.

Mayahara et al. BMC Cancer 2012 12:609   doi:10.1186/1471-2407-12-609

Open Data